Research programme: antibody therapeutics - Adimab/Eli Lilly

Drug Profile

Research programme: antibody therapeutics - Adimab/Eli Lilly

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimab; Eli Lilly
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 18 Jul 2017 Early research is ongoing for an Undefined indication in USA
  • 18 Jul 2017 Adimab expands its research and development agreement with Eli Lilly for antibody therapeutics
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top